MDD

This study tests whether a gentle, at-home brain stimulation device (tDCS) can help people with depression maintain their improvement after successful hospital treatments like rTMS, ECT, or esketamine. Thirty adults who have already improved will use the device for 30 minutes, 5 …

This study tests an experimental drug called LV232 for people with major depressive disorder. About 400 adults aged 18 to 65 will receive either LV232 or a placebo for 8 weeks to see if it reduces depression symptoms. The goal is to find the best dose and check for side effects.

This study tests whether a single 25 mg dose of psilocybin (the active ingredient in magic mushrooms) can ease major depression in 100 adults with cancer. Participants are randomly assigned to receive either the full dose or a very low placebo dose, and depression levels are trac…

This study tests whether giving psilocybin (the active ingredient in magic mushrooms) followed by a type of brain stimulation called aiTBS is safe and can help people with depression that hasn't improved with other treatments. About 100 adults aged 22-65 with treatment-resistant …

This study tests whether taking omega-3 (EPA) supplements for 12 weeks can reduce depressive symptoms in overweight or obese adults with depression and low omega-3 levels. 50 participants will receive either EPA or a placebo. The goal is to see if improving omega-3 status helps m…

This study watches 100 people with depression who are already receiving TMS (transcranial magnetic stimulation) as part of their regular care. Researchers use brain scans and symptom checklists to see if brain network patterns can predict who will respond to TMS. The goal is to u…

This study looks at how stress and inflammation affect the brains of women with major depressive disorder (MDD) or premenstrual dysphoric disorder (PMDD). Researchers will compare brain activity, stress hormones, and immune markers in 75 naturally cycling women (ages 18-40) acros…